Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
CytoSorbents Corporation received a 180-day extension from Nasdaq, until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for its common stock. The company will regain compliance if its share price closes at or above $1.00 for at least 10 consecutive trading days before that date.
The notice has no immediate effect on the Nasdaq listing or SEC reporting, but the company warns there is no assurance it will regain compliance and its stock could be delisted. CytoSorbents is monitoring its share price and is considering options to address the deficiency, including a possible reverse stock split.
Positive
- None.
Negative
- Ongoing Nasdaq listing risk: CytoSorbents remains out of compliance with Nasdaq’s $1.00 minimum bid price rule despite receiving an extension to September 28, 2026, and explicitly states there is no assurance it will regain compliance or avoid potential delisting.
Insights
Nasdaq grants more time, but delisting risk for CytoSorbents remains.
Nasdaq’s Listing Qualifications Staff granted CytoSorbents a further 180 days, until September 28, 2026, to meet the $1.00 minimum bid price requirement. Compliance is restored if the stock trades at or above $1.00 for at least 10 consecutive trading days.
The company previously had a deadline of March 31, 2026 following an initial non‑compliance notice dated October 2, 2025. Management is evaluating options, explicitly including a potential reverse stock split, but clearly notes there is no assurance of regaining compliance or avoiding a Nasdaq delisting.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Extension length: 180 days
Minimum bid price: $1.00 per share
New compliance deadline: September 28, 2026
+3 more
6 metrics
Extension length
180 days
Additional compliance period granted by Nasdaq Listing Qualifications Staff
Minimum bid price
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) requirement for continued listing
New compliance deadline
September 28, 2026
Date by which CytoSorbents must regain minimum bid compliance
Trading days needed at $1.00+
10 consecutive trading days
Condition to regain compliance with the minimum bid rule
Initial non-compliance notice date
October 2, 2025
Nasdaq letter citing 30 consecutive days below $1.00
Prior compliance deadline
March 31, 2026
End of the first 180-day grace period under Rule 5810(c)(3)(A)
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A), Listing Qualifications Staff, +1 more
5 terms
Minimum Bid Price Requirement financial
"to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
"in accordance with Nasdaq Listing Rule 5810(c)(3)(A)"
Listing Qualifications Staff regulatory
"received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC"
Listing qualifications staff are the exchange employees who review and monitor whether a company meets the rules required to be listed on a stock exchange, similar to referees checking that players follow the game’s rules. They assess financial filings, corporate governance, and ongoing disclosures, and can flag problems, request corrective steps, or recommend suspension or delisting. Investors care because their determinations affect a company’s ability to trade publicly and can signal increased risk or regulatory trouble.
reverse stock split financial
"These options include, but are not limited to, effecting a reverse stock split, if necessary."
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
FAQ
What did CytoSorbents (CTSO) announce about its Nasdaq listing status?
CytoSorbents received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule. The extension runs until September 28, 2026, and there is currently no immediate impact on its listing or SEC reporting obligations.
What does CytoSorbents (CTSO) need to do to regain Nasdaq bid price compliance?
To regain compliance, CytoSorbents’ common stock must close at $1.00 per share or more for at least 10 consecutive trading days before September 28, 2026. Achieving this trading pattern would satisfy Nasdaq Listing Rule 5550(a)(2) on minimum bid price.
Why was CytoSorbents (CTSO) originally found non-compliant with Nasdaq rules?
Nasdaq’s staff notified CytoSorbents on October 2, 2025, that the company was not compliant because its closing bid price had been below $1.00 for 30 consecutive business days. An initial 180-day grace period ran until March 31, 2026, before the current extension was granted.
What options is CytoSorbents (CTSO) considering to address the Nasdaq deficiency?
CytoSorbents intends to keep monitoring its share price and is considering available options to resolve the deficiency. The company specifically mentions that these options include, but are not limited to, effecting a reverse stock split if necessary to meet the minimum bid requirement.
Does the Nasdaq extension change CytoSorbents’ (CTSO) current trading status?
The extension has no immediate effect on the listing of CytoSorbents’ common stock on Nasdaq or its SEC reporting. However, the company cautions there can be no assurance it will regain compliance or that its stock will not ultimately be delisted from Nasdaq.
What happens if CytoSorbents (CTSO) fails to meet the $1.00 bid price by September 28, 2026?
If CytoSorbents does not regain compliance by having its stock close at or above $1.00 for 10 consecutive trading days by September 28, 2026, its common stock may be subject to delisting from Nasdaq under the minimum bid price rule, as the company explicitly notes.